COMP and breast cancer: F5 also demonstrated strong similarity to published myCAF signatures, including Elyada myCAF and LRRC15+ fibroblasts from pancreatic cancer, pan-cancer C10_COMP+ CAF, ECM/TGFβ myCAF from breast cancer and Liu myCAF from PCa (Buechler et al., 2021; Elyada et al., 2019; Kieffer et al., 2020; Liu et al., 2023; Qian et al., 2020) (Figure 1H; Supplementary Figures S1E,H).